This report analyzes the US in vitro diagnostics industry, forecasting demand to reach nearly $25 billion by 2016. Clinical chemistry and immunoassay products are expected to remain the top sellers. Molecular diagnostic products will see the fastest growth due to advantages in detecting infectious diseases and cancer. Diabetes testing will also see gains due to increased blood glucose monitoring. The report profiles major industry players and provides historical data and forecasts by product type, application, and market through 2021.
U.S. dependency on foreign pharmaceutical production imposes vulnerability to failure
Authors: Veronika Valdova, D.V.M. and Ronald L Sheckler
Affiliation: Arete-Zoe, LLC
ABSTRACT
Pharmaceutical supply chains have become increasingly complex due to the shift of manufacturing and critical operations to Asia. U.S. pharmaceutical dependency on foreign sole-source production of essential materials imposes vulnerability affecting the entire industry and national health systems from interruption by exposure to natural events and man-made threats, both accidental and criminal as well as political. Sector vulnerabilities stem from complex regulatory landscape, difficulties for enforcement of quality standards at foreign facilities, single-source supply chain resulting from limited sourcing options, increasing shipping distance exposure to both natural events and complicated by maritime chokepoints. Periodic and chronic shortages of many essential products across therapeutic categories have been significant for more than a decade. The Covid-19 crisis aggravated some of these long-standing issues and made the systemic vulnerabilities publicly evident. The combination of limited capacity to exercise control over essential commodities, the long-term trend of outsourcing, with the politicization of business relationships causes the entire pharmaceutical industrial sector to be internationally dependent, creating numerous potentials for systemic failure.
Availability of essential medicines in Hungary (2017)Arete-Zoe, LLC
This report analyzes availability of essential medicines as defined in the World Health Organization (WHO) Essential List Medicines (Report of the WHO Expert Committee) in Hungary. The WHO list of essential medicines contains most effective and safe medicines needed to meet the most important needs in health systems and is frequently used by countries to create their own national lists. Without these drugs, some conditions will not be able to receive optimal therapy. Availability gap represents serious public health concern. Expert Committee of the World Health Organization selects Essential Medicines Lists in accordance with approved procedures. The Committee evaluates the scientific evidence on the basis of the comparative effectiveness, safety and cost-effectiveness of the medicines.
Pharmaceutical Supply Chain Integrity and Security (2016)Arete-Zoe, LLC
The course material serves many interests by facilitating understanding of environment, dynamics, and influences affecting regulatory policies and corporate decision-making that ultimately determine access, availability, and safety of pharmaceutical products. In the first four chapters, we will introduce and describe the regulatory environment in the United States, European Union, in major Asian economies such as Japan, India and China, regulatory policies in Russia, and international standards. Holistic understanding of regulatory environment in global context is essential for understanding of the challenges in pharmaceutical supply chain in the current globalized, inter-connected and inter-dependent economy. In chapter “Enforcement”, we will introduce national enforcement systems in the context of globally operating pharmaceutical industry, and present major initiatives and events. Industry trends such as consolidation, outsourcing of key operations, and shift of manufacturing to Asia determine operational environment. Limited sourcing options, and increasing complexity and distance, affect vulnerability to disruption. Track and trace requirements introduced new vulnerabilities especially in the information management domain.
The material included in these modules serves many interests by facilitating understanding of construct, dynamics, and influences affecting regulatory policies and corporate decision-making that ultimately determine access, availability, and effectiveness of pharmaceutical products. In the following modules we will introduce and describe the highly specialized and often disconnected components of pharmaceutical research, drug development/manufacturing, marketing, regulatory policies and practices, and use case studies to qualify the relative effectiveness of safeguards to prevent harm. Additionally, how have pressures to reduce health care costs or increase safety actually affected both aspects of public concern within a global context because transnational interests influence national circumstances.
Cancer Drugs Dominating Global Orphan Drug Market LandscapeKuicK Research
“Global Orphan Cancer Drug Market & Clinical Pipeline Insight” Report Highlights:
Orphan Cancer Drug Market Outlook
Orphan Drug Designation Criteria: US, Europe & Asia
Reimbursement Policy: US, Europe & Asia
Regulatory Framework: FDA & EMA Guidelines
Orphan Cancer Drugs Clinical Pipeline by Phase, Country & Target Indications
Orphan Cancer Drug Patent Analysis
Orphan Cancer Drug in Development Phase: 235
Majority of Orphan Cancer Drugs in Phase-II: 81
Marketed Orphan Cancer Drugs: 70
U.S. dependency on foreign pharmaceutical production imposes vulnerability to failure
Authors: Veronika Valdova, D.V.M. and Ronald L Sheckler
Affiliation: Arete-Zoe, LLC
ABSTRACT
Pharmaceutical supply chains have become increasingly complex due to the shift of manufacturing and critical operations to Asia. U.S. pharmaceutical dependency on foreign sole-source production of essential materials imposes vulnerability affecting the entire industry and national health systems from interruption by exposure to natural events and man-made threats, both accidental and criminal as well as political. Sector vulnerabilities stem from complex regulatory landscape, difficulties for enforcement of quality standards at foreign facilities, single-source supply chain resulting from limited sourcing options, increasing shipping distance exposure to both natural events and complicated by maritime chokepoints. Periodic and chronic shortages of many essential products across therapeutic categories have been significant for more than a decade. The Covid-19 crisis aggravated some of these long-standing issues and made the systemic vulnerabilities publicly evident. The combination of limited capacity to exercise control over essential commodities, the long-term trend of outsourcing, with the politicization of business relationships causes the entire pharmaceutical industrial sector to be internationally dependent, creating numerous potentials for systemic failure.
Availability of essential medicines in Hungary (2017)Arete-Zoe, LLC
This report analyzes availability of essential medicines as defined in the World Health Organization (WHO) Essential List Medicines (Report of the WHO Expert Committee) in Hungary. The WHO list of essential medicines contains most effective and safe medicines needed to meet the most important needs in health systems and is frequently used by countries to create their own national lists. Without these drugs, some conditions will not be able to receive optimal therapy. Availability gap represents serious public health concern. Expert Committee of the World Health Organization selects Essential Medicines Lists in accordance with approved procedures. The Committee evaluates the scientific evidence on the basis of the comparative effectiveness, safety and cost-effectiveness of the medicines.
Pharmaceutical Supply Chain Integrity and Security (2016)Arete-Zoe, LLC
The course material serves many interests by facilitating understanding of environment, dynamics, and influences affecting regulatory policies and corporate decision-making that ultimately determine access, availability, and safety of pharmaceutical products. In the first four chapters, we will introduce and describe the regulatory environment in the United States, European Union, in major Asian economies such as Japan, India and China, regulatory policies in Russia, and international standards. Holistic understanding of regulatory environment in global context is essential for understanding of the challenges in pharmaceutical supply chain in the current globalized, inter-connected and inter-dependent economy. In chapter “Enforcement”, we will introduce national enforcement systems in the context of globally operating pharmaceutical industry, and present major initiatives and events. Industry trends such as consolidation, outsourcing of key operations, and shift of manufacturing to Asia determine operational environment. Limited sourcing options, and increasing complexity and distance, affect vulnerability to disruption. Track and trace requirements introduced new vulnerabilities especially in the information management domain.
The material included in these modules serves many interests by facilitating understanding of construct, dynamics, and influences affecting regulatory policies and corporate decision-making that ultimately determine access, availability, and effectiveness of pharmaceutical products. In the following modules we will introduce and describe the highly specialized and often disconnected components of pharmaceutical research, drug development/manufacturing, marketing, regulatory policies and practices, and use case studies to qualify the relative effectiveness of safeguards to prevent harm. Additionally, how have pressures to reduce health care costs or increase safety actually affected both aspects of public concern within a global context because transnational interests influence national circumstances.
Cancer Drugs Dominating Global Orphan Drug Market LandscapeKuicK Research
“Global Orphan Cancer Drug Market & Clinical Pipeline Insight” Report Highlights:
Orphan Cancer Drug Market Outlook
Orphan Drug Designation Criteria: US, Europe & Asia
Reimbursement Policy: US, Europe & Asia
Regulatory Framework: FDA & EMA Guidelines
Orphan Cancer Drugs Clinical Pipeline by Phase, Country & Target Indications
Orphan Cancer Drug Patent Analysis
Orphan Cancer Drug in Development Phase: 235
Majority of Orphan Cancer Drugs in Phase-II: 81
Marketed Orphan Cancer Drugs: 70
Global antibody drug conjugate market & pipeline insight2020KuicK Research
" Global Antibody Drug Conjugate Market & Pipeline Insight 2020" Report Highlight:
Global Antibody Drug Conjugates Market Overview
Mechanism of Antibody Drug Conjugates
Global Antibody Drug Conjugates Clinical Pipeline by Company, Indication & Phase
Global Antibody Drug Conjugates Clinical Pipeline: 148 ADC
Marketed Antibody Drug Conjugates Clinical Insight: 8 ADC
Antibody Drug Conjugates Patent Analysis
Global Antibody Drug Conjugates Market Future Prospects
Epigenetics Diagnostic Market Size, Share, Growth, Trends and Forecast Report...Signitech
The global epigenetics diagnostic market size was valued at USD 5.5 billion in 2018 and is estimated to register a CAGR of 18.8% over the forecast period. Increasing prevalence of cancer and other chronic diseases and growing geriatric population are some of the key factors expected to drive the market.
Cancer immunomodulators market & pipeline insight 2020KuicK Research
"Cancer Immunomodulators Market & Pipeline Insight 2020" Report Highlights:
Introduction & Need of Cancer Immunomodulators
Cancer Immunomodulators Mechanism
Cancer Immunomodulators Clinical Pipeline By Company, Indication & Phase
Cancer Immunomodulators Clinical Pipeline: 747 Cancer Immunomodulators Drugs
Majority Cancer Immunomodulators in Preclinical Phase: 300 Marketed Cancer Immunomodulators Clinical Insight
Marketed Cancer Immunomodulators: 47
Cancer Immunomodulators Drug Patent Analysis
United States IVD Market (By Application Segments, Products, Region, End User...iGATE RESEARCH
iGATE Research has released a research report on “United States IVD Market (By Application Segments, Products, Region, End Users) Size, Share, Major Deals & Company Analysis - Forecast to 2025”
Click here to view the complete report: http://igateresearch.com/FullReportDetail.php?p=166
Contact US
iGATE Research PVT LTD
Ravi Sinha
Sales Manager
Marketing and Sales Divison
Email: ravi.sinha@igateresearch.com
Contact: +91-858-684-0791, +91-821-092-7469 (INDIA)
Web: www.igateresearch.com
Global gene therapy market & pipeline insightKuicK Research
“Global Gene Therapy Market & Pipeline Insight” Market Highlight:
Gene Therapy Market Overview
Significance of Gene Therapy in Cancer Therapeutics
Current Applications of Gene Therapy to Cancer Treatment
Gene Therapy Market Dynamics: Drivers, Challenges & Future Outlook
FDA & AMA Guidelines for Gene Therapy
Gene Therapy Pipeline by Phase, Indications, Country & Company
Gene Therapy Pipeline: 246 Drugs
Marketed Gene Therapy: 2 (Gendicine & Rexin-G)
Cancer Gene Therapy Pipeline: 69 Drugs
The transient protein expression market was valued at US$ 660.00 million in 2019 and is projected to reach US$ 983.10 million by 2027; it is expected to grow at a CAGR of 5.3% from 2020 to 2027.
"Global HIV Vaccine Market Future Outlook" Report Highlights:
Introduction to HIV Vaccines
Issues Related to the Development of HIV Vaccines
Parameters for Successful Commercialization of HIV Vaccines
Global HIV Vaccines Market Opportunity Analysis
Global HIV Vaccine Clinical Pipeline by Company & Phase
Global HIV Vaccine Clinical Pipeline: 100 Vaccines
Majority Vaccine in Preclinical Phase: 42 Vaccines
Biomarkers are novel diagnostic tools that provide intelligence to physician about disease progression and treatment effects. Advancement in understanding of human genome promotes its application in diagnosis of disease on molecular basis. Biomarker technology is evidencing increased application in disease diagnosis, drug development and formulation, diagnosis for exposure of certain harmful chemical and prognostic treatments.
Tim Mackey, Assistant Professor, University of California, San Diego - Department of Anesthesiology, speaks about the effect counterfeit Avastin has had on efforts to protect the American public from counterfeit medications.
Global orphan drug market future outlook 2020Rajesh Sarma
"Global Orphan Drug Market Future Outlook 2020" report highlights:
Global Orphan Drug Market Overview
Global Orphan Drug Market Segment Analysis
FDA & EMA Regulation for Clinical Trials Orphan Designated Drugs
Orphan Drug Designation Criteria & Reimbursement Policy by Region
Comprehensive Insight on Global Orphan Drugs Clinical Pipeline & Patent Analysis by Company, Country, Indication & Phase
Global Orphan Drugs Clinical Pipeline: 697 Drugs
Majority Orphan Drugs in Phase-II Trials: 249 Drugs
Marketed Orphan Drugs: 274 Drugs
Daniel Burke, FDA's Senior Special Agent in the Cybercrime Investigations Unit, introduces our 3rd panel at the 2014 Interchange by speaking about how fake online pharmacies can affect American citizens.
IIBMS ANSWER SHEETS
IIBMS MBA CASE STUDY ANSWER SHEETS -
IIBMS MBA CASE STUDY SOLUTIONS -
IIBMS EMBA CASE STUDY ANSWER SHEETS -
IIBMS EMBA CASE STUDY SOLUTIONS -
IIBMS DMS CASE STUDY ANSWER SHEETS -
IIBMS DMS CASE STUDY SOLUTIONS -
IIBMS MMS CASE STUDY ANSWER SHEETS -
IIBMS MIB CASE STUDY SOLUTIONS -
MBA IIBMS ANSWER SHEETS -
EMBA IIBMS CASE STUDY SOLUTIONS -
ACADEMIC WRITING SERVICES -
Global Study Solutions -
Dr. Aravind Banakar -
aravind.banakar@gmail.com -
www.mbacasestudyanswers.com -
9901366442 – 9902787224
Scott A. LaGanga, Executive Director Partnership for Safe Medicines (PSM) and Senior Vice President, Public Affairs - Advocacy at the Pharmaceutical Research and Manufacturers of America (PhRMA), opens PSM's Interchange 2014.
5 Cutting-Edge Trends in Molecular DiagnosticsBruce Carlson
Despite the focus on novelty in this field, it is near 2 decades old. Yet a lot is changing. A look at a few trends that could change molecular diagnostics.
Global antibody drug conjugate market & pipeline insight2020KuicK Research
" Global Antibody Drug Conjugate Market & Pipeline Insight 2020" Report Highlight:
Global Antibody Drug Conjugates Market Overview
Mechanism of Antibody Drug Conjugates
Global Antibody Drug Conjugates Clinical Pipeline by Company, Indication & Phase
Global Antibody Drug Conjugates Clinical Pipeline: 148 ADC
Marketed Antibody Drug Conjugates Clinical Insight: 8 ADC
Antibody Drug Conjugates Patent Analysis
Global Antibody Drug Conjugates Market Future Prospects
Epigenetics Diagnostic Market Size, Share, Growth, Trends and Forecast Report...Signitech
The global epigenetics diagnostic market size was valued at USD 5.5 billion in 2018 and is estimated to register a CAGR of 18.8% over the forecast period. Increasing prevalence of cancer and other chronic diseases and growing geriatric population are some of the key factors expected to drive the market.
Cancer immunomodulators market & pipeline insight 2020KuicK Research
"Cancer Immunomodulators Market & Pipeline Insight 2020" Report Highlights:
Introduction & Need of Cancer Immunomodulators
Cancer Immunomodulators Mechanism
Cancer Immunomodulators Clinical Pipeline By Company, Indication & Phase
Cancer Immunomodulators Clinical Pipeline: 747 Cancer Immunomodulators Drugs
Majority Cancer Immunomodulators in Preclinical Phase: 300 Marketed Cancer Immunomodulators Clinical Insight
Marketed Cancer Immunomodulators: 47
Cancer Immunomodulators Drug Patent Analysis
United States IVD Market (By Application Segments, Products, Region, End User...iGATE RESEARCH
iGATE Research has released a research report on “United States IVD Market (By Application Segments, Products, Region, End Users) Size, Share, Major Deals & Company Analysis - Forecast to 2025”
Click here to view the complete report: http://igateresearch.com/FullReportDetail.php?p=166
Contact US
iGATE Research PVT LTD
Ravi Sinha
Sales Manager
Marketing and Sales Divison
Email: ravi.sinha@igateresearch.com
Contact: +91-858-684-0791, +91-821-092-7469 (INDIA)
Web: www.igateresearch.com
Global gene therapy market & pipeline insightKuicK Research
“Global Gene Therapy Market & Pipeline Insight” Market Highlight:
Gene Therapy Market Overview
Significance of Gene Therapy in Cancer Therapeutics
Current Applications of Gene Therapy to Cancer Treatment
Gene Therapy Market Dynamics: Drivers, Challenges & Future Outlook
FDA & AMA Guidelines for Gene Therapy
Gene Therapy Pipeline by Phase, Indications, Country & Company
Gene Therapy Pipeline: 246 Drugs
Marketed Gene Therapy: 2 (Gendicine & Rexin-G)
Cancer Gene Therapy Pipeline: 69 Drugs
The transient protein expression market was valued at US$ 660.00 million in 2019 and is projected to reach US$ 983.10 million by 2027; it is expected to grow at a CAGR of 5.3% from 2020 to 2027.
"Global HIV Vaccine Market Future Outlook" Report Highlights:
Introduction to HIV Vaccines
Issues Related to the Development of HIV Vaccines
Parameters for Successful Commercialization of HIV Vaccines
Global HIV Vaccines Market Opportunity Analysis
Global HIV Vaccine Clinical Pipeline by Company & Phase
Global HIV Vaccine Clinical Pipeline: 100 Vaccines
Majority Vaccine in Preclinical Phase: 42 Vaccines
Biomarkers are novel diagnostic tools that provide intelligence to physician about disease progression and treatment effects. Advancement in understanding of human genome promotes its application in diagnosis of disease on molecular basis. Biomarker technology is evidencing increased application in disease diagnosis, drug development and formulation, diagnosis for exposure of certain harmful chemical and prognostic treatments.
Tim Mackey, Assistant Professor, University of California, San Diego - Department of Anesthesiology, speaks about the effect counterfeit Avastin has had on efforts to protect the American public from counterfeit medications.
Global orphan drug market future outlook 2020Rajesh Sarma
"Global Orphan Drug Market Future Outlook 2020" report highlights:
Global Orphan Drug Market Overview
Global Orphan Drug Market Segment Analysis
FDA & EMA Regulation for Clinical Trials Orphan Designated Drugs
Orphan Drug Designation Criteria & Reimbursement Policy by Region
Comprehensive Insight on Global Orphan Drugs Clinical Pipeline & Patent Analysis by Company, Country, Indication & Phase
Global Orphan Drugs Clinical Pipeline: 697 Drugs
Majority Orphan Drugs in Phase-II Trials: 249 Drugs
Marketed Orphan Drugs: 274 Drugs
Daniel Burke, FDA's Senior Special Agent in the Cybercrime Investigations Unit, introduces our 3rd panel at the 2014 Interchange by speaking about how fake online pharmacies can affect American citizens.
IIBMS ANSWER SHEETS
IIBMS MBA CASE STUDY ANSWER SHEETS -
IIBMS MBA CASE STUDY SOLUTIONS -
IIBMS EMBA CASE STUDY ANSWER SHEETS -
IIBMS EMBA CASE STUDY SOLUTIONS -
IIBMS DMS CASE STUDY ANSWER SHEETS -
IIBMS DMS CASE STUDY SOLUTIONS -
IIBMS MMS CASE STUDY ANSWER SHEETS -
IIBMS MIB CASE STUDY SOLUTIONS -
MBA IIBMS ANSWER SHEETS -
EMBA IIBMS CASE STUDY SOLUTIONS -
ACADEMIC WRITING SERVICES -
Global Study Solutions -
Dr. Aravind Banakar -
aravind.banakar@gmail.com -
www.mbacasestudyanswers.com -
9901366442 – 9902787224
Scott A. LaGanga, Executive Director Partnership for Safe Medicines (PSM) and Senior Vice President, Public Affairs - Advocacy at the Pharmaceutical Research and Manufacturers of America (PhRMA), opens PSM's Interchange 2014.
5 Cutting-Edge Trends in Molecular DiagnosticsBruce Carlson
Despite the focus on novelty in this field, it is near 2 decades old. Yet a lot is changing. A look at a few trends that could change molecular diagnostics.
Liquid Biopsy Global Market estimated to be worth $8,730.4 million by 2024Vinay Shiva Prasad
Liquid biopsy is a minimally invasive technology for detection of molecular biomarkers without the need for invasive procedures. Raising incidence of cancer and late pregnancies are driving this market.
Cancer Diagnostics Global Market estimated to be worth $10,627.4 million by 2026Vinay Shiva Prasad
Increasing prevalence of different types of cancers, increasing awareness of personalized medicine, national program for cancer control by individual countries, availability of companion diagnostics, growth in the point of care testing, increase in sequencing-based tests and other molecular and immunology based techniques are driving the growth of cancer diagnostics.
“Global HIV Infection Drug Market & Pipeline Insight” Report Highlight:
Global HIV Infection Drug Market Overview & Incidence Scenario
FDA & EMA Regulation for Development of HIV Drug
Global HIV Infection Drug Clinical Pipeline by Phase, Company & Country
Global HIV Clinical Pipeline: 315 Drugs in Development Phases
Majority HIV Drug in Preclinical Phase: 144 Drugs
Marketed HIV Drugs: 37
Suspended & Discounted HIV Drug in Clinical Pipeline: 539 Drugs
Patent Analysis: Patent Number & Technology
Molecular diagnostics market & forecast (by application, technology, countrie...Renub Research
Renub Research (http://renub.com/report/molecular-diagnostics-market-forecast-by-application-technology-countries-companies-clinical-trials-to-2017-global-analysis-114) has announced the addition of the "Molecular Diagnostics Market & Forecast (By Application, Technology, Countries, Companies & Clinical Trials) to 2017: Global Analysis" report to its offering
The polymerase chain reaction (PCR) approach has been demonstrated to be effective in pharmaceutical and biotechnology research, as well as microbiological quality control. The approach is also used in genetic engineering.
As many blockbuster drugs reach their patent cliffs, pharmaceutical companies and their service providers are searching to make drug development a more efficient process. Here are just a few of the trends to look for in the coming years.
Learn more: http://bit.ly/1LSIgwJ
Latin America Point of Care Diagnostics Market Size, Growth | Industry Repo...Uday M
Latin America Point Of Care (PoC) Diagnostics Market Analysis By Product (Glucose Testing, Hb1Ac Testing, Coagulation, Fertility, Cardiac Markers, Infectious Diseases, Primary Acre Systems, Hematology, Decentralized Clinical Chemistry, Feces, Blood Gas Electrolytes, Ambulatory Chemistry, Urinalysis, Drug Abuse Testing, HIV, Clostridium Difficile, HBV, Pneumonia Or Streptococcus Associated Infections) By End-Use (Clinics, Hospital, Home), And Segment Forecasts To 2024
Biological Safety Testing Market Size, Product Analysis and Applications, 201...Signitech
The global biological safety testing market size was valued at USD 2.20 billion in 2016 and is anticipated to exhibit a CAGR of 12.2% during the forecast period.
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
Strand featured in CIO Review: Pharma and Life Science Special edition - July 2014
Strand Genomics Inc recognised by CIO Review as one among 20 most promising Tech solution providers to Pharma and Life science industry 2014
1. In Vitro Diagnostics to 2016
This study analyzes the US in vitro diagnostics industry. It presents historical demand data for the years
2001, 2006 and 2011, and forecasts for 2016 and 2021 by product type (e.g., reagents and consumables,
instruments and systems, clinical chemistry, immunoassay, blood testing, nucleic acid testing,
microbiology, cellular analysis), application (e.g., endocrine conditions, infectious diseases, cancer, drug
testing) and market. The study also considers market environment factors, evaluates company market
share and profiles industry players.
IVD demand in US to reach nearly $25 billion in 2016
US demand for in vitro diagnostic (IVD) products will rise more than six percent annually to nearly $25
billion in 2016. Aging demographic patterns, expanding levels of health insurance coverages, and new
product introductions will underlie gains. Growth in the middle aged and elderly population segments will
boost overall health care needs, leading to a rising volume of IVD tests. The extension of health
insurance coverage attributable to the Affordable Health Care Act of 2010 will make basic and specialized
IVD procedures available to a greater number of individuals. Advances in cellular analysis, molecular
diagnostic and other advanced technologies will expand applications for IVD products in disease
detection, forensic medical, and identity testing.
Clinical chemistry, immunoassay to remain top products
Clinical chemistry and immunoassay will remain the top two IVD methodologies, the former based on
sales of personal blood glucose monitors and test strips and the latter due to the penetration of high
value-added chemiluminescent products into infectious disease and drug testing markets. Molecular
diagnostic products will post the fastest growth in demand among all IVD products based on throughput,
accuracy, and speed advantages, especially in the detection of infectious diseases and cancer markers.
Diabetes testing will remain the largest IVD application through 2016 and beyond due to increasing blood
glucose monitoring among afflicted patients.
Get your copy of this report @ http://www.reportsnreports.com/reports/183965-in-vitro-diagnostics-
to-2016.html
Report Details:
Published: July 2012
No. of Pages: 365
Price: US$5100
Hemostasis tests for cardiac conditions offer best growth
Based on their ability to quantify heart attack and embolism risk prior to occurrence, hemostasis tests for
D-dimer and other cardiac parameters will command the best growth among IVD blood testing products.
2. Demand for molecular diagnostic products will expand at a strong pace as next-generation PCR
(polymerase chain reaction) and FISH (fluorescence in situ hybridization) penetrate applications involving
the analysis, characterization, and therapeutic monitoring of complex infections and tumors. DNA-based
forensic, genetic, and identity testing will comprise one of the fastest growing IVD applications through
2016 as the vast potential of law enforcement and genetic screening markets begins to translate into
significant revenues. Among other IVD products, cellular analysis and anatomical pathology reagents and
instruments will post the best sales gains. Cellular analysis techniques will continue to dominate cervical
cancer testing and penetrate additional cancer diagnostic applications. Anatomical pathology will remain
the leading IVD technique for biopsy-based cancer and infectious disease detection.
Diabetes testing to benefit clinical chemistry reagents & instruments
Evolving epidemiological trends and patient care approaches will impact favorably on growth
opportunities for most types of IVD products. The market for clinical chemistry reagents and instruments
will benefit from an increasing number of diabetic patients engaging in self-blood glucose monitoring and
the expanding use of general health screening in routine patient examinations. The widening availability
of chemiluminescent tests with inherent sensitivity and selectivity advantages will broaden applications for
immunoassays in therapeutic drug monitoring, drugs of abuse detection, and infectious disease testing.
COMPANY PROFILES
Profiles for 27 US competitors such as Abbott Labs, Becton Dickinson, Danaher, Johnson & Johnson,
Life Technologies, Roche Holdings, Siemens Healthcare Diagnostics and Thermo Fisher Scientific
Click here for Reports Related to Biotechnology @ http://www.reportsnreports.com/market-
research/biotechnology/
Contact:
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252.
+ 1 888 391 5441
sales@reportsandreports.com
Connect With Us:
